Vanguard Group
ADPT icon

Vanguard Group’s Adaptive Biotechnologies ADPT Stock Holding History

Vanguard Group’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$183M Buy
11,282,152
+6,983
+0.1% +$114K ﹤0.01% 1586
2025
Q3 		$169M Sell
11,275,169
-4,026
-0% -$49.1K ﹤0.01% 1633
2025
Q2 		$131M Buy
11,279,195
+135,767
+1% +$1.23M ﹤0.01% 1712
2025
Q1 		$82.8M Buy
11,143,428
+428,540
+4% +$3.29M ﹤0.01% 1874
2024
Q4 		$64.2M Buy
10,714,888
+75,448
+0.7% +$416K ﹤0.01% 2059
2024
Q3 		$54.5M Buy
10,639,440
+412,529
+4% +$1.8M ﹤0.01% 2137
2024
Q2 		$37M Sell
10,226,911
-2,642,907
-21% -$8.39M ﹤0.01% 2265
2024
Q1 		$41.3M Buy
12,869,818
+102,134
+0.8% +$395K ﹤0.01% 2249
2023
Q4 		$62.6M Buy
12,767,684
+518,642
+4% +$2.37M ﹤0.01% 2099
2023
Q3 		$66.8M Buy
12,249,042
+196,555
+2% +$1.3M ﹤0.01% 2001
2023
Q2 		$80.9M Buy
12,052,487
+75,073
+0.6% +$558K ﹤0.01% 1964
2023
Q1 		$106M Buy
11,977,414
+183,246
+2% +$1.62M ﹤0.01% 1804
2022
Q4 		$90.1M Buy
11,794,168
+122,385
+1% +$952K ﹤0.01% 1860
2022
Q3 		$83.1M Buy
11,671,783
+95,409
+0.8% +$899K ﹤0.01% 1909
2022
Q2 		$93.7M Buy
11,576,374
+485,540
+4% +$4.27M ﹤0.01% 1864
2022
Q1 		$154M Buy
11,090,834
+59,546
+0.5% +$936K ﹤0.01% 1715
2021
Q4 		$310M Buy
11,031,288
+40,615
+0.4% +$1.24M 0.01% 1331
2021
Q3 		$374M Buy
10,990,673
+813,014
+8% +$29.4M 0.01% 1168
2021
Q2 		$416M Buy
10,177,659
+155,670
+2% +$6.05M 0.01% 1109
2021
Q1 		$403M Buy
10,021,989
+366,564
+4% +$19.8M 0.01% 1087
2020
Q4 		$571M Buy
9,655,425
+2,589,318
+37% +$134M 0.02% 810
2020
Q3 		$344M Buy
7,066,107
+1,424,673
+25% +$59.9M 0.01% 949
2020
Q2 		$273M Buy
5,641,434
+1,169,653
+26% +$42.6M 0.01% 1080
2020
Q1 		$124M Buy
4,471,781
+2,890,710
+183% +$80.6M 0.01% 1400
2019
Q4 		$47.3M Buy
1,581,071
+84,685
+6% +$2.43M ﹤0.01% 2134
2019
Q3 		$46.2M Buy
1,496,386
+1,296,386
+648% +$52.9M ﹤0.01% 2108
2019
Q2 		$9.66M Buy
+200,000
New +$8.86M ﹤0.01% 2880

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $34.9B AUM 72.7% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Vanguard Group's ADPT Position: Q4 2025 in Review

Vanguard Group increased its Adaptive Biotechnologies (ADPT) stake by 0.06% in Q4 2025, buying an estimated $114K and bringing the position to 11,282,152 shares worth $183M. The position accounts for ﹤0.01% of the portfolio, ranked #1586.

Vanguard Group first reported a position in ADPT in Q2 2019 and has held it in 27 quarters since. The position peaked at $571M in Q4 2020. 283 funds tracked by Wall St. Rank hold ADPT as of Q4 2025.

  • Vanguard Group held 11,282,152 shares of Adaptive Biotechnologies worth $183M as of Q4 2025.
  • Vanguard Group bought 6,983 Adaptive Biotechnologies shares in Q4 2025, an estimated $114K.
  • Adaptive Biotechnologies made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #1586 holding.
  • Vanguard Group first reported a position in Adaptive Biotechnologies in Q2 2019 and has held it in 27 quarters since.
  • Vanguard Group's Adaptive Biotechnologies position peaked at $571M in Q4 2020.
  • 283 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.